
BDX Stock Forecast & Price Target
BDX Analyst Ratings
Bulls say
Becton Dickinson is well-positioned for growth and profitability with its diverse business units and success in navigating challenges. The company continues to invest in innovation and strategic acquisitions while also returning money to shareholders through share repurchases and debt reduction. Despite possible risks, BD's long-term outlook remains positive with strong Q1 results and a focus on driving growth and improving margins for increased shareholder returns.
Bears say
Becton Dickinson is a global medical technology company operating in the medical, life sciences, and interventional segments. While the recent launch of key products in the medical essentials and interventional segments show potential for growth, significant challenges in the connected care and biopharma systems divisions remain. Furthermore, the company's recent spin-off with Waters Corporation presents uncertainties about future financial performance. Despite potential upside scenarios, the negative outlook stems from concerns about revenue declines and uncertain impact of the spin-off on shareholder return.
This aggregate rating is based on analysts' research of Becton, Dickinson and Co. and is not a guaranteed prediction by Public.com or investment advice.
BDX Analyst Forecast & Price Prediction
Start investing in BDX
Order type
Buy in
Order amount
Est. shares
0 shares